Cyplasin Biomedical Ltd Announces Australian Patent for the recombinant production of its Antitumor Protein
"From an economic as well as from a scientific point of view the approval of our patent application is important for our company since it protects our approach how to express and obtain a protein made in a tumor cell whereby it itself is cytotoxic to such cells", said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.
Cyplasin-SC TM has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC TM is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. United States and European Patents have been issued to the Company covering the Cyplasin-SC TM protein.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.